Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wall Street Zen

Pliant Therapeutics (NASDAQ:PLRX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $3.00.

Pliant Therapeutics Stock Performance

PLRX stock opened at $1.07 on Friday. Pliant Therapeutics has a one year low of $1.02 and a one year high of $1.95. The firm has a market cap of $66.25 million, a PE ratio of -0.72 and a beta of 1.24. The firm’s 50 day moving average price is $1.11 and its 200-day moving average price is $1.20.

Pliant Therapeutics (NASDAQ:PLRX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Equities research analysts predict that Pliant Therapeutics will post -1.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Pliant Therapeutics

Large investors have recently made changes to their positions in the stock. Rangeley Capital LLC boosted its stake in shares of Pliant Therapeutics by 20.4% in the 2nd quarter. Rangeley Capital LLC now owns 60,220 shares of the company’s stock valued at $70,000 after purchasing an additional 10,220 shares in the last quarter. Algert Global LLC lifted its holdings in Pliant Therapeutics by 17.7% during the 3rd quarter. Algert Global LLC now owns 104,382 shares of the company’s stock worth $154,000 after buying an additional 15,692 shares in the last quarter. Eversept Partners LP boosted its holdings in Pliant Therapeutics by 2.1% in the fourth quarter. Eversept Partners LP now owns 842,023 shares of the company’s stock valued at $1,027,000 after acquiring an additional 17,429 shares during the last quarter. Engineers Gate Manager LP boosted its stake in shares of Pliant Therapeutics by 139.4% in the 2nd quarter. Engineers Gate Manager LP now owns 31,423 shares of the company’s stock valued at $36,000 after purchasing an additional 18,300 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in Pliant Therapeutics by 42.2% during the 1st quarter. Invesco Ltd. now owns 68,963 shares of the company’s stock worth $93,000 after acquiring an additional 20,449 shares during the period. Institutional investors own 97.30% of the company’s stock.

About Pliant Therapeutics

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both ?v?1 and ?v?6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).